Walter J Urba

Summary

Publications

  1. doi request reprint Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy
    Walter J Urba
    Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Urol 180:2011-7; discussion 2017-8. 2008
  2. ncbi request reprint gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 10:668-80. 2004
  3. pmc CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice
    Li Xin Wang
    Laboratory of Cancer Immunobiology, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 40:1375-85. 2010
  4. ncbi request reprint Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide
    Sybren L Meijer
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunother 30:533-43. 2007
  5. ncbi request reprint Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma
    Yiwei Chu
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunother 29:367-80. 2006
  6. ncbi request reprint Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results
    Annemieke Dols
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Hum Gene Ther 14:1117-23. 2003
  7. pmc Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 14:5270-83. 2008
  8. pmc Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing
    Li Xin Wang
    Laboratory of Cancer Immunobiology, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Cancer Res 65:10569-77. 2005
  9. ncbi request reprint Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes
    Hong Ming Hu
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Immunother 27:48-59. 2004
  10. ncbi request reprint Immunotherapy for melanoma: the good, the bad, and the future
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, 4805 N E Glisan, Portland, OR 97213, USA
    Curr Oncol Rep 7:383-92. 2005

Collaborators

Detail Information

Publications41

  1. doi request reprint Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy
    Walter J Urba
    Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Urol 180:2011-7; discussion 2017-8. 2008
    ..This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor...
  2. ncbi request reprint gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 10:668-80. 2004
    ..The data further support the combined use of tetramer binding and functional assays in correlated ex vivo and IVS settings as a standard for immunomonitoring of cancer vaccine patients...
  3. pmc CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice
    Li Xin Wang
    Laboratory of Cancer Immunobiology, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 40:1375-85. 2010
    ..Our results demonstrate the lymphopenia-driven proliferation of CD122+CD8+ Treg in reconstituted lymphodepleted mice limited the antitumor efficacy of DC vaccination in conjunction with adoptive transfer of tumor-specific T cells...
  4. ncbi request reprint Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide
    Sybren L Meijer
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunother 30:533-43. 2007
    ....
  5. ncbi request reprint Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma
    Yiwei Chu
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunother 29:367-80. 2006
    ..Thus, augmentation of vaccine induced antitumor immunity in docetaxel-treated mice primarily due to the enhanced survival of antigen-experienced T cells...
  6. ncbi request reprint Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results
    Annemieke Dols
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Hum Gene Ther 14:1117-23. 2003
    ..This immunization strategy proved to be safe and feasible, and induced tumor-specific immune responses in a minority of patients; however, no objective tumor regressions were observed...
  7. pmc Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 14:5270-83. 2008
    ..We sought to characterize the phenotype and function of gp100 peptide-specific memory CD8+ T cells in melanoma patients after primary gp100(209-2M) immunization and assess the anamnestic response to boosting immunization...
  8. pmc Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing
    Li Xin Wang
    Laboratory of Cancer Immunobiology, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Cancer Res 65:10569-77. 2005
    ....
  9. ncbi request reprint Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes
    Hong Ming Hu
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Immunother 27:48-59. 2004
    ..IFN-gamma production by T cells was comparable after stimulation with peptide-pulsed dimers, T2 cells, or autologous dendritic cells. Peptide-loaded A2 dimers could also be used directly to stimulate T cells in the ELISPOT assay...
  10. ncbi request reprint Immunotherapy for melanoma: the good, the bad, and the future
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, 4805 N E Glisan, Portland, OR 97213, USA
    Curr Oncol Rep 7:383-92. 2005
    ..Although this strategy is extremely challenging, one can expect technological advances that may simplify this approach and further improve outcome...
  11. ncbi request reprint Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine
    Sybren L Meijer
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA
    Cell Immunol 227:93-102. 2004
    ..Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy...
  12. doi request reprint Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 15:2541-51. 2009
    ..The aim of this study was to characterize the primary gp100(209-2M)-specific T-cell response in vaccine-draining, metastases-free lymph nodes and peripheral blood of peptide-vaccinated stage I to III melanoma patients...
  13. ncbi request reprint Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells
    Shawn M Jensen
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunol 170:2014-21. 2003
    ..Additionally, these data emphasize that the enhanced ability to mount a type 1-polarized immune response is inconsequential if a sufficient antitumor immune response is not primed by the tumor...
  14. pmc Signaling through OX40 enhances antitumor immunity
    Shawn M Jensen
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Semin Oncol 37:524-32. 2010
    ..Combining strategies that prime tumor-specific T cells together with OX40 signaling could generate and maintain a therapeutic antitumor immune response...
  15. ncbi request reprint Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses
    John W Smith
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St, 5F40, Portland, OR 97213 2967, USA
    J Clin Oncol 21:1562-73. 2003
    ..To measure the CD8+ T-cell response to a melanoma peptide vaccine and to compare an every-2-weeks with an every-3-weeks vaccination schedule...
  16. ncbi request reprint Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells
    Dominik Ruttinger
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Exp Metastasis 21:305-12. 2004
    ..Considering the promising early findings in the present study, further studies exploring the therapeutic potential of adoptive immunotherapy for metastatic disease to the skeleton are warranted...
  17. ncbi request reprint Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data
    Ulf Petrausch
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, Portland, Oregon 97213, USA
    Cytometry A 69:1162-73. 2006
    ....
  18. ncbi request reprint Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells
    Annemieke Dols
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA
    J Immunother 26:163-70. 2003
    ....
  19. ncbi request reprint Allogeneic breast cancer cell vaccines
    Annemieke Dols
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, OR 97213, USA
    Clin Breast Cancer 3:S173-80. 2003
    ..Allogeneic tumor cell vaccines are safe, feasible, and associated with low toxicity, and the early clinical results suggest that they are worthy of further study..
  20. pmc Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy
    Yuhuan Li
    Laboratory of Cancer Immunobiology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 17:7047-57. 2011
    ....
  21. pmc Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies
    Hauke Winter
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA
    Immunology 108:409-19. 2003
    ..These results provide insights into the development of a protective anti-tumour immune response and strengthen the hypothesis that a T1 cytokine response is critical for T-cell-mediated tumour regression...
  22. pmc Multiple vaccinations: friend or foe
    Sarah E Church
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Portland Medical Center, USA
    Cancer J 17:379-96. 2011
    ....
  23. pmc Science gone translational: the OX40 agonist story
    Andrew D Weinberg
    Providence Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Immunol Rev 244:218-31. 2011
    ..This review describes the journey from in vitro experiments through preclinical mouse models to the successful translation of the first OX40 agonist to the clinic for the treatment of patients with cancer...
  24. ncbi request reprint Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
    John W Smith II
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Oregon, USA
    J Immunother 26:130-8. 2003
    ....
  25. pmc Cross-presentation of tumor associated antigens through tumor-derived autophagosomes
    Yuhuan Li
    Laboratory of Cancer Immunobiology, Providence Portland Medical Center, 4805 N E Glisan Street, Portland, OR 97213, USA
    Autophagy 5:576-7. 2009
    ..The exact nature or form of the antigens derived from donor cells at the time of delivery to the APC for cross-presentation is very controversial...
  26. ncbi request reprint Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
    Jun Ma
    Laboratory of Molecular and Tumor Immunology, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, USA
    Eur J Immunol 33:2123-32. 2003
    ....
  27. pmc Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects
    Ulf Petrausch
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, 4805 NE Glisan Street, Portland, OR 97213, USA
    Curr Mol Med 9:673-82. 2009
    ..Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings...
  28. ncbi request reprint Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study
    Andrew D Weinberg
    Earle A Chiles Research Institute, Robert W Franz Cancer Center, Providence Portland Medical Center, 5F40, Portland, OR 97213, USA
    J Immunother 29:575-85. 2006
    ..These studies demonstrate the immune-stimulatory properties and safety of anti-OX40 in primates and provide a strong scientific rationale to pursue clinical trials in humans...
  29. pmc Efficient cross-presentation depends on autophagy in tumor cells
    Yuhuan Li
    Laboratory of Cancer Immunobiology, Providence Portland Medical Center, OR 97213 2967, USA
    Cancer Res 68:6889-95. 2008
    ....
  30. doi request reprint Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses
    Steven K Seung
    Earle A Chiles Research Institute, Portland, OR 97213, USA
    Sci Transl Med 4:137ra74. 2012
    ....
  31. doi request reprint Integrating new therapies in the treatment of advanced melanoma
    Brendan D Curti
    Providence Cancer Center, Portland, OR 97213, USA
    Curr Treat Options Oncol 13:327-39. 2012
    ..Selected patients can benefit from surgical resection or radiation to manage oligometastatic disease...
  32. ncbi request reprint Undefined-antigen vaccines
    Hong Ming Hu
    Laboratory of Cancer Immunobiology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA
    Cancer Treat Res 123:207-25. 2005
    ....
  33. pmc Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
    Nicholas P Morris
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 N E Glisan Street, Portland, OR 97213, USA
    Mol Immunol 44:3112-21. 2007
    ..Our ultimate goal is to use this recombinant molecule in a future clinical trial, and we feel that the OX40L hexamer will have equivalent or superior agonist activity in vivo when compared to an anti-OX40 antibody...
  34. ncbi request reprint TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunol 170:2004-13. 2003
    ..These insights could be used to monitor and potentially tune the immune response to cancer vaccines...
  35. ncbi request reprint CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells
    Hong Ming Hu
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, OR 97213, USA
    J Immunol 169:4897-904. 2002
    ..Thus, cross-priming of therapeutic CD8(+) T cells by a tumor vaccine transduced with GM-CSF requires TNFR, IL-12, and CD28 signaling...
  36. ncbi request reprint Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells
    Sybren L Meijer
    Laboratory of Molecular and Tumor Immunology, Earle A Chiles Research Institute, Providence Portland Medical Center, Oregon 09713, USA
    J Immunother 25:359-72. 2002
    ..No objective tumor regressions were observed. MHC class I restricted, tumor-specific cytokine secretion was observed in lymphocytes from TVDLN and the peripheral blood of vaccinated patients...
  37. ncbi request reprint Development of antitumor immune responses in reconstituted lymphopenic hosts
    Hong Ming Hu
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Cancer Res 62:3914-9. 2002
    ..Vaccination is best performed concomitantly with reconstitution; delayed vaccination resulted in T cells with less therapeutic activity...
  38. ncbi request reprint Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    Eric J Small
    University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
    Clin Cancer Res 13:3883-91. 2007
    ..The immunotherapy, based on the GVAX platform, is a combination of two prostate carcinoma cell lines modified with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene...
  39. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  40. ncbi request reprint Are all hypotheses generated before data analysis prospective?
    Walter J Urba
    J Clin Oncol 20:1431-3. 2002
  41. pmc Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:2292-8. 2008
    ..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial...